A recent National Academies of Sciences, Engineering, and Medicine report details several adverse impacts from poor diversity in clinical trials. These include lack of access to effective medical interventions, compounding of health disparities in underrepresented and excluded populations, and hindering innovation. Read the Full Article.
Lack of diversity in clinical trials costs billions of dollars. Incentives can spur innovation
